AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104GlobeNewsWire • 09/23/26
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764GlobeNewsWire • 08/20/26
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026GlobeNewsWire • 07/07/26
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's DiseaseGlobeNewsWire • 06/30/26
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's DiseaseGlobeNewsWire • 06/11/26
AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 06/03/26
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALSGlobeNewsWire • 05/22/26
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and CareGlobeNewsWire • 05/15/26
AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 05/14/26
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's DiseaseGlobeNewsWire • 04/30/26
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with LillyGlobeNewsWire • 04/07/26
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 03/18/26
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 03/13/26